$8.75
Sage Therapeutics


Performance
Dividends
1W
1M
YTD
1Y
3Y
21/36
Growth
Score
12/36
Dividend
Score
Valuation
PE Ratio
-1.53
PS Ratio
11.56
RSI
-
0
PEG Ratio
-0.12
0
PRG Ratio
-0.12
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
172.88%
3
Gross Margin
81.37%
3
Current Ratio
9.13
Return on Assets
-75.46%
Return on Equity
-68.99%
Return on inv. Capital
-90.62%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 41.24M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -400.67M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 31.80M
2018
2019
2020
2021
2022
2023
2024
6
Events

SAGE
Sage Therapeutics
in 271 days
after market close
Earnings per Share is expected with - and revenue with - .

SAGE
Sage Therapeutics
in 194 days
after market close
Earnings per Share is expected with - and revenue with - .

SAGE
Sage Therapeutics
in 89 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
18.07.2014
MaketCap
547.95M
Country
US
CEO
Barry E. Greene
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Updated 23.07.2025